title: Comparison of polymethoxyethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts.
abstract: OBJECTIVE
  The relative benefits of strategic leukofiltration on polymer-coated and low-dose heparin protocol on heparin-coated circuits were studied across EuroSCORE patient risk strata for three different cohorts.
  
  
  METHODS
  In a prospective, randomized study, 270 patients undergoing coronary artery bypass grafting were allocated into three groups (n = 90): Group 1 - polymethoxyethylacrylate-coated circuits + leukocyte filters; Group 2 - polypeptide-based heparin-bonded circuits with reduced heparinization; and Group 3--CONTROL: uncoated circuits. Each group was further divided into three subgroups (n = 30), with respect to low- (EuroSCORE 0-2), medium- (3-5), and high- (6+) risk patients. Blood samples were collected at T1: following induction of anesthesia; T2: following heparin administration; T3: 15 min after CPB; T4: before cessation of CPB; T5: 15 min after protamine reversal; and T6: ICU.
  
  
  RESULTS
  In high-risk cohorts, leukocyte counts demonstrated significant differences at T4 and T5 in Group 1, and at T4 in Group 2. Platelet counts were preserved significantly better at T4 and T5 in both groups (p < 0.05 versus control). Serum IL-2 and C3a levels were significantly lower at T3, T4 and T5 in Group 1, and T4 and T5 in Group 2 (p < 0.05). Postoperative bleeding, respiratory support time and incidence of atrial fibrillation were lower in the study groups versus control. Cell counts on filter mesh and heparin-coated fibers/ circuits were significantly higher in the high-risk cohorts versus uncoated fibers. Phagocytic capacity increased on filter mesh, especially in high-risk specimens. SEM evaluation demonstrated better preserved coated circuits.
  
  
  CONCLUSIONS
  Leukofiltration and coating reduced platelet adhesion, protein adsorption, atrial fibrillation and reduced heparinization acted via modulation of systemic inflammatory response in high-risk groups.
authors.affiliation: University of K Kale, Kirikale, Turkey. sgunaydin@isnet.net.tr
authors.forename: Serdar
authors.initials: S
authors.lastname: Gunaydin
authors.forename: Kevin
authors.initials: K
authors.lastname: McCusker
authors.forename: Venkataramana
authors.initials: V
authors.lastname: Vijay
authors.forename: Selim
authors.initials: S
authors.lastname: Isbir
authors.forename: Tamer
authors.initials: T
authors.lastname: Sari
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Onur
authors.forename: Aylin
authors.initials: A
authors.lastname: Gurpinar
authors.forename: Aysun
authors.initials: A
authors.lastname: Sezgin
authors.forename: Mustafa F
authors.initials: MF
authors.lastname: Sargon
authors.forename: Tevfik
authors.initials: T
authors.lastname: Tezcaner
authors.forename: Yaman
authors.initials: Y
authors.lastname: Zorlutuna
mesh_terms: D000179:Acrylates; D000925:Anticoagulants / Q000008:administration & dosage*; D000990:Antithrombin III / Q000378:metabolism; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000517:prevention & control; D039481:CD11b Antigen / Q000378:metabolism; D018821:CD18 Antigens / Q000378:metabolism; D002478:Cells, Cultured; D020099:Coated Materials, Biocompatible; D015331:Cohort Studies; D001026:Coronary Artery Bypass / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data*; D003324:Coronary Artery Disease / Q000453:epidemiology / Q000601:surgery*; D005342:Fibrinolysis; D005374:Filtration; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D047589:Leukocyte Reduction Procedures; D007962:Leukocytes / Q000166:cytology / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D010973:Platelet Adhesiveness; D011108:Polymers; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000179:Acrylates; D000925:Anticoagulants; D039481:CD11b Antigen; D018821:CD18 Antigens; D020099:Coated Materials, Biocompatible; D011108:Polymers; C046193:antithrombin III-protease complex; C413485:poly(2-methoxyethylacrylate); D000990:Antithrombin III; D006493:Heparin; D010447:Peptide Hydrolases